BioLineRx : Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024

SECURITIES AND EXCHANGE COMMISSION


WASHINGTON, D.C. 20549


FORM 6-K


REPORT OF FOREIGN PRIVATE ISSUER


...

Related Keywords

United States ,Modiin ,Israel General ,Israel ,New York ,Russia ,Georgia ,Washington ,Georgia World Congress Center ,Atlanta ,Ukraine ,American ,Russian ,John Lacey ,Twitterand Linkedin ,Moran Meir ,Jeffreyr Skaar ,Philipa Serlin ,Lifesci Advisors ,International Society For Pharmacoeconomics ,Outcomes Research ,Exchange Commission On ,Securities Exchange ,Value In Health ,Society For Health Economics ,Biolinerx Ltd ,American Cancer Society ,Biolinerx United States Inc ,Trinity Life Sciences ,Ma Ayan Street ,Principal Executive Offices ,Securities Exchange Act ,Linerx Announces Poster Presentation ,Economic Model Data ,Hematopoietic Stem Cell Mobilization ,Multiple Myeloma ,Presentation Today ,International Society ,Professional Society ,Health Economics ,World Congress Center ,Institutional Level Impact ,Additional Apheresis Days ,Healthcare Resource Utilization ,Jenniferl Lessor ,Biolinerx United States ,Economic Evaluation ,Hypersensitivity Reactions ,Site Reactions ,Cell Mobilization ,Tumor Cell Mobilization ,Private Securities Litigation Reform Act ,Exchange Commission ,Key Statistics About Multiple ,Sci Advisors ,Markets ,